BRPI0519242A2 - uso derivados de 1-aminociclohexano para o tratamento de esclerose méltipla, instabilidade emocional e paralisia pseudobulbar - Google Patents
uso derivados de 1-aminociclohexano para o tratamento de esclerose méltipla, instabilidade emocional e paralisia pseudobulbarInfo
- Publication number
- BRPI0519242A2 BRPI0519242A2 BRPI0519242-0A BRPI0519242A BRPI0519242A2 BR PI0519242 A2 BRPI0519242 A2 BR PI0519242A2 BR PI0519242 A BRPI0519242 A BR PI0519242A BR PI0519242 A2 BRPI0519242 A2 BR PI0519242A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- multiple sclerosis
- emotional instability
- pseudobulbar paralysis
- aminocyclohexane derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
USO DE DERIVADOS DE l-AMINOCICLOHEXANO PARA O TRATAMENTO DE ESCLEROSE MéLTIPLA, INSTABILIDADE EMOCIONAL E PARALISIA PSEUDOBULBAR. A presente invenção relaciona-se ao tratamento de indivíduos diagnosticados com esclerose múltipla, instabilidade emocional ou paralisia pseudobulbar que compreende a administração ao referido individual de uma quantidade eficaz.de um derivado de l-aminociclohexano, ou seja, especialmente memantina ou neramexano.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63842304P | 2004-12-22 | 2004-12-22 | |
PCT/US2005/046733 WO2006069294A1 (en) | 2004-12-22 | 2005-12-22 | 1-aminocyclohexane-derivatives for the treatment of multiple sclerosis emotional lability and pseudobulbar affect |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0519242A2 true BRPI0519242A2 (pt) | 2009-01-06 |
Family
ID=36084339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0519242-0A BRPI0519242A2 (pt) | 2004-12-22 | 2005-12-22 | uso derivados de 1-aminociclohexano para o tratamento de esclerose méltipla, instabilidade emocional e paralisia pseudobulbar |
Country Status (13)
Country | Link |
---|---|
US (2) | US20060205822A1 (pt) |
EP (1) | EP1838297A1 (pt) |
JP (1) | JP2008525488A (pt) |
KR (1) | KR20070086507A (pt) |
CN (1) | CN101087599A (pt) |
AU (1) | AU2005319078A1 (pt) |
BR (1) | BRPI0519242A2 (pt) |
CA (1) | CA2589671A1 (pt) |
EA (1) | EA200701351A1 (pt) |
IL (1) | IL183963A0 (pt) |
MX (1) | MX2007007416A (pt) |
WO (1) | WO2006069294A1 (pt) |
ZA (1) | ZA200705112B (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070141148A1 (en) * | 2005-11-30 | 2007-06-21 | Merz Pharma Gmbh & Co. Kgaa | Neramexane MR matrix tablet |
GB0623897D0 (en) * | 2006-11-30 | 2007-01-10 | Pliva Istrazivanje I Razvoj D | Pharmaceutical composition of memantine |
TW200916091A (en) * | 2007-06-08 | 2009-04-16 | Merz Pharma Gmbh & Amp Co Kgaa | Neramexane for the treatment of nystagmus |
CN101801365A (zh) | 2007-09-12 | 2010-08-11 | 莫茨药物股份两合公司 | 治疗耳鸣的间隔疗法 |
JP5882208B2 (ja) * | 2009-07-30 | 2016-03-09 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドによるクローン病の治療 |
AU2010282948C1 (en) | 2009-08-10 | 2017-03-02 | Active Biotech, Ab | Treatment of BDNF-related disorders using laquinimod |
SG183513A1 (en) * | 2010-03-03 | 2012-09-27 | Teva Pharma | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
MX337614B (es) * | 2010-03-03 | 2016-03-10 | Teva Pharma | Tratamiento de lupus nefritis usando laquinimod. |
WO2012048871A1 (en) * | 2010-10-12 | 2012-04-19 | Merz Pharma Gmbh & Co. Kgaa | Memantine for improving cognitive performance in subjects |
EP2640391B1 (en) | 2010-11-15 | 2015-11-11 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
KR20130124518A (ko) * | 2010-12-07 | 2013-11-14 | 테바 파마슈티컬 인더스트리즈 리미티드 | 다발경화증 환자의 피로를 감소시키고, 기능 상태를 개선시키고, 삶의 질을 개선시키기 위한 라퀴니모드의 용도 |
CN102241678B (zh) | 2011-04-26 | 2014-10-29 | 辽宁利锋科技开发有限公司 | 含有脂环结构化合物的抗肿瘤作用与应用 |
EP2766020A4 (en) | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
SG11201404214QA (en) | 2012-02-03 | 2014-08-28 | Teva Pharma | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
AU2013361057A1 (en) * | 2012-12-21 | 2015-07-30 | Teva Pharmaceutical Industries Ltd. | Oral transmucosal delivery of glatiramer acetate |
TWI508461B (zh) * | 2013-01-04 | 2015-11-11 | Mstar Semiconductor Inc | 適用於數位電視廣播系統的信號處理方法以及接收器 |
WO2015095783A1 (en) | 2013-12-20 | 2015-06-25 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
SG11201608674UA (en) | 2014-04-29 | 2016-11-29 | Teva Pharma | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
JP6987384B2 (ja) | 2015-06-19 | 2021-12-22 | エージンバイオ, インコーポレイテッド | ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 |
EP3474831A1 (en) | 2016-06-23 | 2019-05-01 | Corium International, Inc. | Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent |
KR102424270B1 (ko) | 2016-07-27 | 2022-07-25 | 코리움, 인크. | 경구 전달과 생물학적으로 동등한 약물동역학을 가진 경피 전달 시스템 |
SG11201900712SA (en) | 2016-07-27 | 2019-02-27 | Corium Int Inc | Memantine transdermal delivery systems |
CN109789106B (zh) | 2016-07-27 | 2023-06-27 | 考里安有限责任公司 | 碳酸氢钠原位转化驱动胺药物的透皮递送 |
US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
WO2019126531A1 (en) | 2017-12-20 | 2019-06-27 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
BR112020026062B1 (pt) | 2018-06-19 | 2023-04-04 | Agenebio, Inc | Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson |
EP4103187A4 (en) * | 2020-02-10 | 2024-04-10 | Woolsey Pharmaceuticals, Inc. | METHODS FOR TREATING PSEUDOBULBAR AFFECTION AND OTHER EMOTIONAL DISORDERS |
WO2024039886A1 (en) | 2022-08-19 | 2024-02-22 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA974518A (en) * | 1972-04-20 | 1975-09-16 | Merz And Co. | Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds |
DE2856393C2 (de) * | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
US5366738A (en) * | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
US6024983A (en) * | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
US4849222A (en) * | 1987-03-24 | 1989-07-18 | The Procter & Gamble Company | Mixtures for treating hypercholesterolemia |
US5506231A (en) * | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
US5334618A (en) * | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
DE10299048I2 (de) * | 1989-04-14 | 2006-07-13 | Merz Pharma Gmbh & Co Kgaa | Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie |
US5614560A (en) * | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
US5206248A (en) * | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
US5863529A (en) * | 1995-09-20 | 1999-01-26 | Mayo Foundation For Medical Education And Research | Suppression of demyelination by interleukin-6 |
US6071966A (en) * | 1997-06-30 | 2000-06-06 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane NMDA receptor antagonists |
TW593225B (en) * | 1997-06-30 | 2004-06-21 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexane NMDA receptor antagonists |
US6828462B2 (en) * | 2001-11-07 | 2004-12-07 | Merz Pharma Gmbh & Co. Kgaa | Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
TW200306189A (en) * | 2002-03-21 | 2003-11-16 | Merz Pharma Gmbh & Co Kgaa | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
TWI326214B (en) * | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
AU2003251993A1 (en) * | 2002-07-19 | 2004-02-09 | Inge Grundke-Iqbal | NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau |
US20040132826A1 (en) * | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
US20050065219A1 (en) * | 2003-03-27 | 2005-03-24 | Lipton Stuart A. | Treatment of demyelinating conditions |
US8039009B2 (en) * | 2004-06-17 | 2011-10-18 | Forest Laboratories Holdings Limited | Modified release formulations of memantine oral dosage forms |
-
2005
- 2005-12-21 US US11/315,581 patent/US20060205822A1/en not_active Abandoned
- 2005-12-22 BR BRPI0519242-0A patent/BRPI0519242A2/pt not_active IP Right Cessation
- 2005-12-22 WO PCT/US2005/046733 patent/WO2006069294A1/en active Application Filing
- 2005-12-22 MX MX2007007416A patent/MX2007007416A/es not_active Application Discontinuation
- 2005-12-22 AU AU2005319078A patent/AU2005319078A1/en not_active Abandoned
- 2005-12-22 CA CA002589671A patent/CA2589671A1/en not_active Abandoned
- 2005-12-22 JP JP2007548505A patent/JP2008525488A/ja not_active Withdrawn
- 2005-12-22 CN CNA2005800443634A patent/CN101087599A/zh active Pending
- 2005-12-22 EA EA200701351A patent/EA200701351A1/ru unknown
- 2005-12-22 EP EP05855316A patent/EP1838297A1/en not_active Withdrawn
- 2005-12-22 KR KR1020077014105A patent/KR20070086507A/ko not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183963A patent/IL183963A0/en unknown
- 2007-06-18 ZA ZA200705112A patent/ZA200705112B/xx unknown
-
2008
- 2008-08-05 US US12/221,574 patent/US20090081259A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN101087599A (zh) | 2007-12-12 |
CA2589671A1 (en) | 2006-06-29 |
MX2007007416A (es) | 2007-08-15 |
KR20070086507A (ko) | 2007-08-27 |
EP1838297A1 (en) | 2007-10-03 |
WO2006069294A1 (en) | 2006-06-29 |
US20090081259A1 (en) | 2009-03-26 |
EA200701351A1 (ru) | 2007-12-28 |
US20060205822A1 (en) | 2006-09-14 |
JP2008525488A (ja) | 2008-07-17 |
AU2005319078A1 (en) | 2006-06-29 |
ZA200705112B (en) | 2008-10-29 |
IL183963A0 (en) | 2008-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0519242A2 (pt) | uso derivados de 1-aminociclohexano para o tratamento de esclerose méltipla, instabilidade emocional e paralisia pseudobulbar | |
CL2008001721A1 (es) | Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales. | |
BRPI0410503B8 (pt) | composição tópica e uso da composição | |
AR048878A1 (es) | Composiciones topicas de metadona y metodos para usarlas | |
BRPI0715396B8 (pt) | método de produção de uma composição para vacina | |
CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
BRPI0612669B8 (pt) | composição imunogênica, vacina, composição, e composição liofilizada | |
BRPI0717845A2 (pt) | Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos | |
DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
MX337081B (es) | Anticuerpo anti-nr10 y su uso. | |
BRPI0515316A (pt) | compostos de imidazoquinolina | |
BRPI0514474A (pt) | multiparticulados | |
BRPI0210568B8 (pt) | conjugado, uso de um conjugado, e, composição farmacêutica | |
BRPI0905369B8 (pt) | composição farmacêutica, uso da composição farmacêutica e kit compartimentado | |
CL2008003537A1 (es) | Compuestos derivados de 2-amino-pirimidina, antagonistas de receptores h4; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad alergica, inmunologica o inflamatoria o dolor. | |
BRPI1010369B8 (pt) | composição cosmética em forma de nanoemulsão óleo-em-água e uso de uma composição | |
BRPI0607084A2 (pt) | uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto | |
BR112012022243A8 (pt) | Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico | |
CL2007002380A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica. | |
CL2007002619A1 (es) | Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion. | |
GT200600106A (es) | Agentes endoparasiticidas | |
CL2007002975A1 (es) | Composicion farmaceutica de liberacion modificada que comprende microesferas recubiertas con un farmaco musculo relajante y un farmaco aine; proceso de preparacion y uso en el tratamiento de espasticidad, desordenes relacionados con padecimientos musculares y/o musculo esqueleticos. | |
CL2009000665A1 (es) | Compuestos derivados de pirrolidinilo; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la ansiedad, depresion o ambas. | |
BRPI0506630A (pt) | composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada | |
CL2009001089A1 (es) | Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |